The chairman of Sinovac Biotech (Sinovac)(NasdaqGS:SVA), a vaccine focused biopharmaceutical company in China, Yin Weidong, has said the company hopes to supply its experimental COVID-19 vaccine to more South American countries by outsourcing some manufacturing procedures to a partner in Brazil, Reuters news agency reported on Thursday.

Sinovac plans to provide semi-finished products to its partner Instituto Butantan, which will perform filling and packaging and supply finished items to other South American countries.

Reportedly, China has included Sinovac's vaccine candidate CoronaVac in its emergency use programme launched in July 2020, but late-stage trials overseas have not been completed, arousing safety concerns among experts.

In a news conference, Yin said the company was willing to collaborate and share data with other countries on vaccine emergency use if they need such programmes, and is in talks with Chile, among other nations, on conducting Phase 3 clinical studies.

According to Reuters, global vaccine makers, such as Sinovac and AstraZeneca, have partnered with Brazil to conduct late-stage trials of their vaccine candidates in South America's largest nation, battling with the third highest tally of infections worldwide.